Chimeric marker vaccine candidates, vGPE/PAPeV E and vGPE/PhoPeV E, have been generated and their efficacy and capability to differentiate infected from vaccinated animals were confirmed in previous studies. The safety profile of the two chimeric marker vaccine candidates, particularly in the potential reversion to virulence, was evaluated. Each virus was administered to pigs with a dose equivalent to the vaccination dose, and pooled tonsil homogenates were subsequently inoculated into further pigs. Chimeric virus vGPE/PAPeV E displayed the most substantial attenuation, achieving this within only two passages, whereas vGPE/PhoPeV E was detectable until the third passage and disappeared entirely by the fourth passage. The vGPE strain, assessed alongside, consistently exhibited stable virus recovery across each passage without any signs of increased virulence in pigs. In vitro assays revealed that the type I interferon-inducing capacity of vGPE/PAPeV E was significantly higher than that of vGPE/PhoPeV E and vGPE. In conclusion, the safety profile of the two chimeric marker vaccine candidates was affirmed. Further research is essential to ensure the stability of their attenuation and safety in diverse pig populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11281528PMC
http://dx.doi.org/10.3390/v16071120DOI Listing

Publication Analysis

Top Keywords

chimeric marker
16
marker vaccine
16
safety profile
12
profile chimeric
12
vaccine candidates
12
reversion virulence
8
chimeric
5
assessment safety
4
marker
4
vaccine
4

Similar Publications

Objective: To identify clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma (LUAD) and to evaluate survival after brain metastasis.

Methods: Patients who underwent complete resection of stage I-IIIA LUAD between 2011 and 2020 were included. A subset of patients had broad-based panel next-generation sequencing performed on their tumors.

View Article and Find Full Text PDF

Thyroid-stimulating hormone receptor antibody (TRAb) is a specific marker for Graves' disease (GD) and the measurement of which can improve the accuracy of GD diagnosis. Current detection methods utilize porcine-derived polyclonal-TRAb, which is unstable and is a source of significant inter-assay variability. This study aims to establish a time-resolved fluorescence immunoassay (TRFIA) method based on stable source of recombinant human TSHR and TRAb for the detection of serum TRAb.

View Article and Find Full Text PDF

Prognostic assessment in chronic lymphocytic leukemia (CLL) is essential for delivery of timely, personalized therapy. status, karyotype, IGHV mutational status, minimal residual disease (MRD), gene mutations and markers of cell proliferation were important prognostic tools in the era of chemo-immunotherapy (CIT). With BCL2 inhibitors (BCL2i), outcome is still impacted by IGHV status, status, complex karyotype, and achievement of undetectable MRD.

View Article and Find Full Text PDF

Fish Brain Cell Lines Can Be Infected with Adenoviral Vectors and Support Transgene Expression-An In Vitro Approach.

Int J Mol Sci

December 2024

Immunobiology for Aquaculture Group, Department of Cell Biology and Histology, Faculty of Biology, University of Murcia, 30100 Murcia, Spain.

Host-pathogen interactions and the design of vaccines for aquaculture fish viruses are challenging and call for innovative approaches. This study explores the potential of adenoviral (Ad) vectors Ad5 and chimeric Ad5/40 as gene delivery tools for fish brain cells susceptible to neurotropic viruses. For this purpose, European sea bass () DLB-1 and gilthead seabream () SaB-1 brain cell lines were infected with Ad5 or Ad5/40 vectors expressing GFP, and we evaluated their capacity for infection by fluorescence microscopy and flow cytometry, as well as their antiviral innate immune response by the transcription of gene markers ( and ).

View Article and Find Full Text PDF

Background And Study Aims: As a novel immunotherapy, chimeric antigen receptor T (CAR-T) cell technology is successful in treating hematologic malignancies, and exhibits potential benefits in partial solid tumors. Therapies targeting one antigen have some weaknesses, and dual-targeted CAR-T cells may be a better option. Alpha-fetoprotein (AFP) and glypican-3 (GPC3) are both highly expressed in hepatocellular carcinoma (HCC) and serve as important markers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!